Adults 18 to 100, any sex, with Spinal Cord Injuries or Deglutition Disorders. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants Displaying Unsafe SwallowingPrimary· Baseline (single timepoint only)
The Penetration-Aspiration Scale is an 8-point categorical scale that is used to characterize swallowing safety for each bolus based on the depth to which any material enters the airway and whether or not the material is ejected. Levels 1 and 2 on the scale are considered safe, while levels \> 2 are considered unsafe. Actual scale scores (1-8) will be recorded and then converted to binary categorical scores (\< 3 vs \>/= 3). We report the frequency (count) of participants showing unsafe swallowing (i.e., scores \> 2) by bolus consistency.
Group
Value
95% CI
Thin Liquid Barium
0
Slightly Thick Liquid Barium
0
Mildly Thick Liquid Barium
0
Moderately Thick Liquid Barium
0
Extremely Thick Liquid Barium
0
Number of Participants Displaying Post-swallow InhalationPrimary· Baseline (single timepoint only)
Healthy swallowing typically occurs partway through an outward breath, such that the direction of breathing both before and after the swallow is exhalation. Whenever a swallow is followed immediately by inhalation, this is considered abnormal and a risk for food or liquid material to be sucked into the airway. We measured the direction of breathing before and after swallows via nasal cannula using the airflow module of the KayPentax Digital Swallow Workstation Swallowing Signals Lab. We report the frequency (percentage) of participants displaying at least one swallow showing post-swallow inhal
Group
Value
95% CI
Thin Liquid Barium
2
Slightly Thick Liquid Barium
5
Mildly Thick Liquid Barium
3
Moderately Thick Liquid Barium
1
Extremely Thick Liquid Barium
2
Duration of the Respiratory Pause Seen in SwallowingPrimary· Baseline (single timepoint only)
Healthy swallowing typically occurs partway through an outward (exhalatory) breath, and involves a pause in breathing. The duration of this respiratory pause was measured in milliseconds for each swallow based on the continuous airflow waveform collected via nasal cannula using the airflow module of the KayPentax Digital Swallow Workstation Swallowing Signals Lab. We report means and standard deviations for respiratory pause duration by consistency. Shorter respiratory pause durations reflect inadequate airway protection.
Group
Value
95% CI
Thin Liquid Barium
901
± 485
Slightly Thick Liquid Barium
996
± 573
Mildly Thick Liquid Barium
867
± 455
Moderately Thick Liquid Barium
721
± 275
Extremely Thick Liquid Barium
815
± 541
Sponsor's own description
This study is part of a larger grant, for which the overall goal is to collect measurements of liquid flow through the oropharynx (i.e., mouth and throat) during swallowing.The focus of this study is to evaluate the flow of liquids of varying consistency in the spinal disorder population.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury
· NA
· recruiting
NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial
· NA
· recruiting
NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury
· NA
· recruiting
NCT07488793 — Remote Ischemic Conditioning for PwSCI
· NA
· recruiting
NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP)
· NA
· recruiting
Other University Health Network, Toronto trials
Trials by the same sponsor.
NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response
· NA
· recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U
· Phase 2
· not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis
· Phase 2
· not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas
· Phase 2
· not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 4 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04114604.